The purpose of the Tissue Core (TC) is to help the facilitate the scientific needs of peer-reviewed. Cancer Center investigators by providing a collection of centralized services and technologies focused around high quality, richly-annotated human biospecimens. The TC is organized in four distinct operational sections that provide end-to-end biorepository services required for the collection, processing, annotation, storage and ultimate release of biospecimens. The TC-lntake & Acquisition section is responsible for the collection and initial annotation and de-identification of biospecimens for investigator driven and general banking protocols. The TC-Sample Processing Lab provides a wide variety of biospecimen processing services ranging from processing of blood to extraction of nucleic acids. The TC-Research Histology Services section supports CCSG investigators by offering basic histology services, research focused immunohistochemistry and construction of Tissue Microarray. The TC-Lifetime Cancer Screening operates as a Tissue Core satellite facility at the Center's Lifetime Cancer Screening and Prevention Center. The technical staff is responsible for operating and maintaining core instrumentation and technology. Over the last grant period, the Core established sophisticated, state-of-the-science technologies to support Immunohistochemistry (Ventana Discovery Automated System), automated, high-throughput nucleic acid extraction systems, (Qiagen) and most recently a Shared Instrumentation Grant funded automated freezer system. A new biospecimen inventory management system (LabVantage Biobanking) was also launched. The new LabVantage Biobanking system provides centralized comprehensive sample management, consent verification and biospecimen de-identification allowing the core to effectively serve as an institutional Honest Broker. Access to biospecimens and Tissue Core services are governed by regularly updated biospecimen collection and utilization policies and well-defined chargeback mechanism. Collectively, all four TC sections are heavily utilized by all 5 research programs and provide support for over 90 investigator-initiated protocols. The Core requests CCSG Support of $400,966, which is 24% of its operational budget. Over 75% of total users are Moffitt members and peer-reviewed.
With highly trained staff, the Tissue Core provides Moffitt members with a state-of-the-art centralized biorepository, processing and histology services to conduct extensive cancer research. The significant investment in infrastructure as well as state of the art equipment and instrumentation provides a large and efficient biospecimen resource for Moffitt members.
|Davis, Stacy N; Govindaraju, Swapamthi; Jackson, Brittany et al. (2018) Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry. Nurs Res 67:212-221|
|Martínez, Úrsula; Brandon, Thomas H; Sutton, Steven K et al. (2018) Associations between the smoking-relatedness of a cancer type, cessation attitudes and beliefs, and future abstinence among recent quitters. Psychooncology 27:2104-2110|
|Perales-Puchalt, Alfredo; Perez-Sanz, Jairo; Payne, Kyle K et al. (2018) Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 103:799-805|
|Nelson, Ashley M; Jim, Heather S L; Small, Brent J et al. (2018) Sleep disruption among cancer patients following autologous hematopoietic cell transplantation. Bone Marrow Transplant 53:307-314|
|Singh, Kshipra; Coburn, Lori A; Asim, Mohammad et al. (2018) Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res 78:4303-4315|
|Kasting, Monica L; Giuliano, Anna R; Reich, Richard R et al. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. Cancer Epidemiol Biomarkers Prev 27:503-513|
|Denson, Aaron; Burke, Nancy; Wapinsky, Georgine et al. (2018) Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol 41:133-139|
|Betts, Brian C; Bastian, David; Iamsawat, Supinya et al. (2018) Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A 115:1582-1587|
|Pidala, Joseph; Beato, Francisca; Kim, Jongphil et al. (2018) In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica 103:531-539|
|Hampras, S S; Tommasino, M; Zhao, Y et al. (2018) Cross-sectional associations between cutaneous viral infections and regulatory T lymphocytes in circulation. Br J Dermatol :|
Showing the most recent 10 out of 1254 publications